Bei Gene, Ltd. BGNE
We take great care to ensure that the data presented and summarized in this overview for BeiGene, Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BGNE
View all-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion20.22% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Capital International Investors Los Angeles, CA4.89MShares$1.11 Billion0.2% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million9.68% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.02MShares$231 Million0.03% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.01MShares$229 Million1.13% of portfolio
-
Black Rock Inc. New York, NY959KShares$217 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il537KShares$122 Million0.02% of portfolio
-
Siren, L.L.C. New York, NY510KShares$116 Million6.39% of portfolio
-
Marshall Wace, LLP London, X0468KShares$106 Million0.13% of portfolio
Latest Institutional Activity in BGNE
Top Purchases
Top Sells
About BGNE
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at BGNE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 14
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
39,936
-41.08%
|
$12,140,544
$304.7 P/Share
|
Aug 14
2025
|
Xiaobin Wu President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
39,936
+34.35%
|
$6,269,952
$157.35 P/Share
|
Aug 13
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
49,858
-29.51%
|
$15,106,974
$303.99 P/Share
|
Aug 13
2025
|
Xiaobin Wu President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
49,858
+42.6%
|
$8,226,570
$165.05 P/Share
|
Aug 13
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
11,013
-91.18%
|
$3,303,900
$300.4 P/Share
|
Aug 13
2025
|
Chan Henry Lee SVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
8,230
+40.93%
|
$1,448,480
$176.75 P/Share
|
Aug 01
2025
|
Aaron Rosenberg Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,190
-100.0%
|
$345,100
$290.47 P/Share
|
Jul 30
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
259
-100.0%
|
$78,995
$305.0 P/Share
|
Jul 30
2025
|
Chan Henry Lee SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
920
-100.0%
|
$279,680
$304.6 P/Share
|
Jul 29
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
4,041
-55.25%
|
$1,224,423
$303.03 P/Share
|
Jul 18
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Indirect |
700
-100.0%
|
$210,000
$300.0 P/Share
|
Jul 09
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
27,802
-63.75%
|
$7,033,906
$253.58 P/Share
|
Jun 24
2025
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
2,007
-65.73%
|
$531,855
$265.81 P/Share
|
Jun 23
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,028
-100.0%
|
$267,280
$260.0 P/Share
|
Jun 23
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,174
-98.42%
|
$831,588
$262.24 P/Share
|
Jun 23
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
1,363
-100.0%
|
$354,380
$260.0 P/Share
|
Jun 17
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
470
-100.0%
|
$117,970
$251.37 P/Share
|
Jun 17
2025
|
John Oyler Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,460
-100.0%
|
$373,760
$256.49 P/Share
|
Jun 17
2025
|
Xiaobin Wu President and COO |
SELL
Open market or private sale
|
Direct |
630
-100.0%
|
$157,500
$250.87 P/Share
|
Jun 16
2025
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
1,177
-71.46%
|
$313,082
$266.4 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.23M shares |
---|---|
Exercise of conversion of derivative security | 9.09M shares |
Open market or private sale | 20.6M shares |
---|---|
Bona fide gift | 159K shares |
Other acquisition or disposition | 29.6K shares |
Payment of exercise price or tax liability | 1.99M shares |